Cannabis Investor Donates $9 Million For Research at Harvard and MIT
In the subdued light of microscope room, Amanda Vernon reviews an image of cells in a mouse brain with Professor Myriam Heiman. (Robin Lubbock/WBUR)

Cannabis Investor Donates $9 Million For Research at Harvard and MIT

A New York-based cannabis investor, Bob Broderick, gifted a $9 million endowment to aid in cannabis research at MIT and Harvard. Broderick, who has made tens of millions of dollars investing in the legal marijuana industry in Canada, is hoping this donation will kickstart cannabis research at two of America’s leading universities. The donation is the largest private sum thus far for the study of cannabis. "I saw an opportunity to take a kind of a leadership position in getting these two great cultural institutions involved in the discussion of cannabis in the country," Broderick told WBUR in Boston.  …

Continue Reading

Senator Mitch McConnell Seeking to Fix Broken Hemp Regulations

U.S. Senate Majority Leader Mitch McConnell (R-KY) and Kentucky Agriculture Commissioner Ryan Quarles hosted a hemp forum on April 8, 2019 at the Kentucky Exposition Center in Louisville. Senator McConnell and Commissioner Quarles invited U.S. Department of Agriculture (USDA) Under Secretary for Marketing and Regulatory Programs Greg Ibach and Risk Management Agency (RMA) Administrator Martin Barbre to update and hear directly from Kentucky hemp farmers, processors and manufacturers regarding the implementation of the 2018 Farm Bill provisions that legalized the production of hemp. USDA Secretary Sonny Perdue, said, “I’d like to thank Senate Majority Leader McConnell and Commissioner Quarles for…

Continue Reading
CVS and Walgreens Now Selling CBD Products in Over 2,300 Stores
A CBD prodcut end-cap at a CVS in Denver, CO is almost completely sold out of product as of April 1, 2019. Credit: coNectar

CVS and Walgreens Now Selling CBD Products in Over 2,300 Stores

Both CVS and Walgreens are now selling CBD products. Despite some conflicting directives from the FDA on CBD-infused products, both national pharmacy/grocery chains are marching ahead with the sales of cannabidiol (CBD) consumer goods. The non-psychoactive component to the cannabis plant, CBD is known to relieve many ailments including anxiety, inflammation and even more acute conditions such as epilepsy and tumor growth. Earlier in 2018, the FDA and the DEA approved the first CBD-infused drug, Epidiolex, which treats certain aggressive types of epilepsy that impact children. Since the December 2018 passage of the 2018 Farm Bill, and the resulting legalization…

Continue Reading
Close Menu